Physician profile
Mae Janiga
NPI 1891263497
$3,277.33
in general payments reported to CMS, 2019-2025
26 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $286 · 2023: $740 · 2024: $1,114 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,955 · Education: $36.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,954.75 |
| Education | $36.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.24 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $325.30 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $293.16 | 2023-2025 | Otezla, Evenity, Prolia |
| Glaxosmithkline, LLC. | $233.08 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $192.82 | 2024-2025 | Voquezna |
| Dexcom, INC. | $180.72 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $178.19 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $170.85 | 2024-2025 | |
| Pfizer INC. | $161.34 | 2023-2025 | |
| Qol Medical, LLC | $128.49 | 2023-2025 | Sucraid, Sucraid |
| Xeris Pharmaceuticals, INC. | $120.70 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Lilly USA, LLC | $105.56 | 2023-2025 | Mounjaro, Jardiance, Lyumjev |
| Bayer Healthcare Pharmaceuticals INC. | $75.74 | 2022-2023 | |
| Ibsa Pharma INC. | $61.96 | 2022-2023 | Tirosint, Licart |
| Ardelyx, INC. | $61.65 | 2024-2025 | Ibsrela |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $57.63 | 2025 | Freestyle Libre 3 |
| Boston Scientific Corporation | $54.83 | 2022-2024 | |
| Daiichi Sankyo INC. | $53.73 | 2023-2025 | Injectafer |
| Exact Sciences Corporation | $46.88 | 2024-2025 | Cologuard Collection Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $43.61 | 2023-2024 | Lifevest |
| Corcept Therapeutics | $39.56 | 2024-2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.41 | 2025 | Xifaxan |
| Viatris Specialty LLC | $20.09 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $19.09 | 2023 | Verquvo, Belsomra, Steglatro |
| Radius Health, INC. | $17.00 | 2024 | Tymlos |
| Antares Pharma, INC. | $14.70 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mae Janiga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.